Subscribe
Growing in APAC: Swedish probiotic firm Probi expands China market via new deal with Sinopharm Foreign Trade By Tingmin Koe Swedish probiotic firm Probi is expanding its presence in APAC via a new deal with China National Pharmaceutical Foreign Trade Corporation (Sinopharm Foreign Trade).
Established in 1981, Sinopharm Foreign Trade is a wholly-owned subsidiary of China National Pharmaceutical Group Corporation, also widely known as Sinopharm – one of the China companies that have successfully developed COVID-19 vaccines.
Under the partnership, Sinopharm Foreign Trade will be launching probiotic products for immune health, bone health, and iron absorption with probiotic strains backed by Probi’s research and clinical data.